Form 4: GeneDx Holdings Corp. CFO Kevin Feeley Reports Stock Transactions

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock related to restricted stock units.

Summary

• On June 16, 2024, Kevin Feeley, the CFO of GeneDx Holdings Corp., acquired 7,197 shares of Class A Common Stock upon the vesting of restricted stock units (RSUs).
• Also on June 16, 2024, 7,197 shares were disposed of to cover tax withholding obligations related to the RSU vesting.
• On June 17, 2024, Feeley sold 2,646 shares of Class A Common Stock at an average price of $28.31 per share.
• Following these transactions, Feeley directly owns 37,409 shares of Class A Common Stock and 79,166 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, which is common in the biotechnology and genomics industry. It provides transparency into the trading activities of key personnel and their holdings in the company.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, including those in the genomics sector like Illumina (ILMN) and Pacific Biosciences (PACB).
• The 'sell to cover' transaction for tax obligations is a common method used by employees receiving equity compensation.
• The vesting schedule of 6.25% quarterly over four years is a typical vesting arrangement for restricted stock units.

Stakeholder Impact

• Shareholders are informed about the stock transactions of a key executive, providing transparency into insider activity.
• The transactions may have a minor impact on the stock price due to the sale of shares.

Key Dates